Genmab — Februar 2021
-
-
-
Det virker ikke som om det er bispefikke andibodies? Så kan de vel ikke være så potentente som Genmabs kandidater?
-
-
if someone here can take on this job of Director of Marketing (DOM), Multiple Myeloma Bi-specifics at JNJ pls, we'll have some inside info on teclistamab and talquetamab
https://jobs.jnj.com/jobs/2105898342W?lang=en-us -
You should take that E L.It is almost a local position for you - Pennsylvania Dutch
-
-
Factors influencing response to talquetamab in myeloma https://www.youtube.com/watch?v=BeUaENS8204&feature=youtu.be (
not sure if it was posted before) -
Almost E L
-
Bristol Myers Squibb writes off $470M as second BCMA CAR-T is ejected from the pipeline https://endpts.com/all-in-on-ide-cel-bristol-myers-squibb-writes-off-470m-for-dropping-a-second-bcma-car-t/
-
I never see it as good news when a cancer drug fails
-
But its still good to be updated. So thanks
for that EL -
Er det ikke kernen i markedsøkonomi. BMS kan bruge pengene bedre et andet sted.
-
Set ud fra en investorvinkel: Good news!!! Set ud fra en kræftbehandlingsvinkel: faktisk også good news, da pengene i udviklingsafdelingen vurderes brugt bedre på andre kandidater. Vi kan sagtens diskutere det fordnuftige i BMS's prioritering af deres udviklingsmidler, men fuldt bevidst at indtage en anden synsvinkel for at bashe en udmelding skrevet klart ud fra investorvinklen, endda med smiley, helt ærligt, troldmanden...
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind